Hyzetimibe

Small moleculeexperimental

Clinical trial activity

4 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
4
Phase 3
3
Phase 4
0

Earliest trial started Mar 1, 2014 (NCT02087917)

Timeline

2010s

  1. Jan 1, 2014

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2015

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • CholesterolSEQUESTERING AGENT

    Cholesterol sequestering agent

Chemistry & pharmacology

Loading structure…

SMILES

O=C1[C@H](C/C=C(\CO)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1
Mol. weight
421.44 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • hs-25
  • hs-25

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03433196Phase 3Jun 7, 2016Peking University, Zhejiang Hisun Pharmaceutical Co. Ltd.
NCT03413462Phase 3Apr 12, 2016Peking University, Zhejiang Hisun Pharmaceutical Co. Ltd.
NCT03464682Phase 3Feb 28, 2015Zhejiang Hisun Pharmaceutical Co. Ltd., Zhejiang University
NCT02087917Phase 2Mar 1, 2014Covance, Zhejiang Hisun Pharmaceutical Co. Ltd.
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Zhejiang Hisun Pharmaceutical Co. Ltd.For profit4422014
Peking UniversityAcademic/Hospital2012016
CovanceFor profit1012014
Zhejiang UniversityAcademic/Hospital1012015
4 organizations
Page 1 / 1